MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - MLTX

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics, alleging that the company made materially false and misleading statements regarding its drug candidate SLK and its comparison to BIMZELX [1]. Group 1: Allegations - The lawsuit claims that during the class period from March 10, 2024, to September 29, 2025, the defendants failed to disclose that SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F [1]. - It is alleged that SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. - The complaint states that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, undermining the defendants' positive statements about SLK's superiority [1]. - The lawsuit argues that the defendants lacked a reasonable basis for their optimistic claims regarding SLK compared to monoclonal antibodies [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased MLTX shares during the specified class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].